Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma

Emmanuelle Jeannot, Véronique Becette, Maura Campitelli, Marie-Ange Calméjane, Emmanuelle Lappartient, Evelyne Ruff, Stéphanie Saada, Allyson Holmes, Dominique Bellet, Xavier Sastre-Garau, Emmanuelle Jeannot, Véronique Becette, Maura Campitelli, Marie-Ange Calméjane, Emmanuelle Lappartient, Evelyne Ruff, Stéphanie Saada, Allyson Holmes, Dominique Bellet, Xavier Sastre-Garau

Abstract

Specific human papillomavirus genotypes are associated with most ano-genital carcinomas and a large subset of oro-pharyngeal carcinomas. Human papillomavirus DNA is thus a tumour marker that can be detected in the blood of patients for clinical monitoring. However, data concerning circulating human papillomavirus DNA in cervical cancer patients has provided little clinical value, due to insufficient sensitivity of the assays used for the detection of small sized tumours. Here we took advantage of the sensitive droplet digital PCR method to identify circulating human papillomavirus DNA in patients with human papillomavirus-associated carcinomas. A series of 70 serum specimens, taken at the time of diagnosis, between 2002 and 2013, were retrospectively analyzed in patients with human papillomavirus-16 or human papillomavirus-18-associated carcinomas, composed of 47 cases from the uterine cervix, 15 from the anal canal and 8 from the oro-pharynx. As negative controls, 18 serum samples from women with human papillomavirus-16-associated high-grade cervical intraepithelial neoplasia were also analyzed. Serum samples were stored at -80°C (27 cases) or at -20°C (43 cases). DNA was isolated from 200 µl of serum or plasma and droplet digital PCR was performed using human papillomavirus-16 E7 and human papillomavirus-18 E7 specific primers. Circulating human papillomavirus DNA was detected in 61/70 (87%) serum samples from patients with carcinoma and in no serum from patients with cervical intraepithelial neoplasia. The positivity rate increased to 93% when using only serum stored at -80°C. Importantly, the two patients with microinvasive carcinomas in this series were positive. Quantitative evaluation showed that circulating viral DNA levels in cervical cancer patients were related to the clinical stage and tumour size, ranging from 55 ± 85 copies/ml (stage I) to 1774 ± 3676 copies/ml (stage IV). Circulating human papillomavirus DNA is present in patients with human papillomavirus-associated invasive cancers even at sub-clinical stages and its level is related to tumour dynamics. Droplet digital PCR is a promising method for circulating human papillomavirus DNA detection and quantification. No positivity was found in patients with human papillomavirus-associated high grade cervical intraepithelial neoplasia.

Keywords: anal carcinoma; carcinoma of the head and neck; cervical carcinoma; circulating HPV DNA; ddPCR.

Figures

Figure 1
Figure 1
Detection of circulating HPV16 E7 DNA by ddPCR in serum samples from patients with HPV16‐associated cervical carcinoma. (A) Stage II invasive cervical carcinoma (Case N°25); Positive plots are represented in blue (4530 copies/ml); No positive droplets detected from patients with CIN3 or from the negative control. (B) Positive detection in the serum of patients with tonsil (case N°65) and oropharyngeal (case N°69) carcinomas (215 and 4605 copies/ml, respectively). (C) Positive detection in the serum of two patients (cases N°1 and N°12) with micro‐invasive cervical carcinoma (32 and 249 copies/ml, respectively). Positive DNA controls from HPV16 tumour tissues and non‐DNA controls, replaced by elution buffer in no template control (NTC), are indicated.
Figure 2
Figure 2
Rate of c‐HPV DNA (log scale) detected using ddPCR in patients with cervical neoplasias according to clinical criteria. Statistical analysis using t‐test [with Welch's correction for plots (B) to (F)]. In B only stage I and II were compared.
Figure 3
Figure 3
Positive correlation between c‐HPV DNA level (log scale) and tumour size in patients with cervical cancer (n = 37). Spearman correlation: r = 0.51 (p = 0.001). (○) Stage I and (•) stage II/III/IV tumours.
Figure 4
Figure 4
Comparison of c‐HPV DNA levels (log scale) detected using ddPCR in serum and plasma samples from patients diagnosed with HPV‐associated invasive carcinoma of the uterine cervix (A) or the anal canal or oropharyngeal region (B).

References

    1. Schwarzenbach H, Hoon DS, Pantel K. Cell‐free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426–437.
    1. Diaz LA, Jr. , Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32: 579–586.
    1. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005; 102: 16368–16373.
    1. Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, et al Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 2015; 7: 1034–1047.
    1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342–350.
    1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890–907.
    1. Alemany L, Saunier M, Alvarado‐Cabrero I, Quiros B, Salmeron J, Shin HR, et al Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2014; 136: 98–107.
    1. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294–4301.
    1. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008; 110: S4–S7.
    1. Hopman AH, Smedts F, Dignef W, Ummelen M, Sonke G, Mravunac M, et al Transition of high‐grade cervical intraepithelial neoplasia to micro‐invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 2004; 202: 23–33.
    1. Herrick J, Conti C, Teissier S, Thierry F, Couturier J, Sastre‐Garau X, et al Genomic organization of amplified MYC genes suggests distinct mechanisms of amplification in tumorigenesis. Cancer Res 2005; 65: 1174–1179.
    1. Peter M, Stransky N, Couturier J, Hupe P, Barillot E, de Cremoux P, et al Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J Pathol 2010; 221: 320–330.
    1. Sathish N, Abraham P, Peedicayil A, Sridharan G, John S, Shaji RV, et al HPV DNA in plasma of patients with cervical carcinoma. J Clin Virol 2004; 31: 204–209.
    1. Kay P, Allan B, Denny L, Hoffman M, Williamson AL. Detection of HPV 16 and HPV 18 DNA in the blood of patients with cervical cancer. J Med Virol 2005; 75: 435–439.
    1. Dong SM, Pai SI, Rha SH, Hildesheim A, Kurman RJ, Schwartz PE, et al Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol Biomarkers Prev 2002; 11: 3–6.
    1. Widschwendter A, Blassnig A, Wiedemair A, Muller‐Holzner E, Muller HM, Marth C. Human papillomavirus DNA in sera of cervical cancer patients as tumor marker. Cancer Lett 2003; 202: 231–239.
    1. Pornthanakasem W, Shotelersuk K, Termrungruanglert W, Voravud N, Niruthisard S, Mutirangura A. Human papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer 2001; 1: 2.
    1. Yang HJ, Liu VW, Tsang PC, Yip AM, Tam KF, Wong LC, et al Quantification of human papillomavirus DNA in the plasma of patients with cervical cancer. Int J Gynecol Cancer 2004; 14: 903–910.
    1. Gnanamony M, Peedicayil A, Subhashini J, Ram TS, Rajasekar A, Gravitt P, et al Detection and quantitation of HPV 16 and 18 in plasma of Indian women with cervical cancer. Gynecol Oncol 2010; 116: 447–451.
    1. Campitelli M, Jeannot E, Peter M, Lappartient E, Saada S, de la Rochefordiere A, et al Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One 2012; 7: e43393.
    1. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, et al Absolute quantification by droplet digital PCR versus analog real‐time PCR. Nat Methods 2013; 10: 1003–1005.
    1. Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N, et al Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 2007; 67: 9364–9370.
    1. Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, et al Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013; 8: e55943.
    1. Dahlstrom KR, Li G, Hussey CS, Vo JT, Wei Q, Zhao C, et al Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. Cancer 2015; 121: 3455–3464.
    1. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al Detection of circulating tumor DNA in early‐ and late‐stage human malignancies. Sci Transl Med 2014; 6: 224ra224.
    1. Holmes A, Lameiras S, Jeannot E, Marie Y, Castera L, Sastre‐Garau X, et al Mechanistic signatures of HPV insertions in cervical carcinomas. NPJ Genom Med 2016; 1: 16004.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner